In patients with an established indication for SGLT2 inhibition—such as CKD, T2DM, or chronic heart failure—these agents may reasonably be considered within a broader, individualized management strategy that also addresses hyperuricemia. This evidence concerns the gene SLC5A2 and chronic kidney disease.